ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025
Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Distinct virological relapse (VR) has occurred after stopping the use of nucleos(t)ide analogues treatment in patients with chronic hepatitis B (CHB) who are positive for Hepatitis B e antigen (HBeAg). Here, we aimed to identify serum miR-146a and miR155 in HBeAg-positive patients with CHB and their relationship with VR after entecavir (ETV) discontinuance. Materials and Methods: Ninety-eight patients with CHB and positive for HBeAg before initiating treatment were analyzed. Virological relapse was defined as 2 consecutive examinations (3 months apart) after treatment discontinuance, both showing an HBV DNA load of more than >2000 IU/mL. Results: Compared to control, CHB patients were observed with increases in serum miR-146a and miR-155 before starting ETV treatment (P < .001). There were 52 patients (53.1%) experiencing VR at 12 months after discontinuance of ETV treatment. The VR group was demonstrated with increases in serum miR-146a and miR-155 than the non-VR group before starting ETV treatment (P < .001). Whether at the beginning of ETV discontinuance or at 12 months after ETV discontinuance, the VR group was noted with elevations in serum miR-146a and miR-155 than the non-VR group (P < .001). Conclusion: The findings demonstrated that miR-146a and miR-155 levels in the circulation may be promising assessment tools for identifying sustained-virological responders after ETV discontinuance in CHB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.